A Look At PROCEPT BioRobotics (PRCT) Valuation After New European Aquablation Guideline Upgrade
Why the new European guidelines matter for PROCEPT BioRobotics (PRCT)
The European Association of Urology has upgraded Aquablation therapy to a strong recommendation for benign prostatic hyperplasia, a shift backed by multiple clinical trials and expanding international guideline support.
See our latest analysis for PROCEPT BioRobotics.
Despite the strong guideline upgrade, PROCEPT BioRobotics' 90 day share price return of 18.34% and 1 year total shareholder return of 50.97% indicate pressure on sentiment, with momentum recently weak rather than building.
If you are comparing this story with other opportunities in medical technology, it may be worth scanning a wider group of healthcare focused AI names using the 36 healthcare AI stocks.
With the shares down about 18% over 90 days and 51% over 1 year, yet sitting below the average analyst price target, is PROCEPT BioRobotics now trading at a discount or is the market already banking on future growth?
Most Popular Narrative: 23% Undervalued
Compared with the narrative fair value of $32.50, PROCEPT BioRobotics' last close at $25.12 suggests a gap that the most followed thesis seeks to explain.
The analyst price target for PROCEPT BioRobotics has been revised from about $50.73 to $32.50 as analysts factor in recent Q4 misses, reduced 2026 guidance, questions around market penetration for Aquablation, and concerns about execution on sales and discounting changes in a competitive BPH market.
Want to understand why a lower growth and margin profile still supports a higher fair value than today? The narrative leans heavily on long run revenue expansion, margin improvement and a reset earnings multiple that remains above the sector. Curious how those ingredients combine into a $32.50 outcome rather than the old target? The full storyline joins those moving parts together.
Result: Fair Value of $32.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you also need to weigh execution risks around Aquablation adoption and ongoing operating losses, which could challenge the long-run margin and earnings story.
Find out about the key risks to this PROCEPT BioRobotics narrative.
Another Take: Price To Sales Sends A Different Signal
The fair value case around $32.50 leans on long run growth and margin improvement, but the simple P/S picture is less forgiving. PROCEPT BioRobotics trades at 4.6x sales, richer than the US Medical Equipment industry at 2.6x, and above a fair ratio of 3x, even if it sits below a 5.1x peer average. That mix of premium to the wider group and discount to closer peers leaves you weighing whether current pricing reflects upside potential or embeds valuation risk if expectations soften.
For a closer look at what this pricing gap could mean in practice, it is worth checking the valuation breakdown via the See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If you are seeing mixed signals on growth, margins and valuation and want to get ahead of the crowd, use the 2 key rewards and 2 important warning signs to weigh both sides for yourself.
Looking for more investment ideas?
If PRCT is only one piece of your watchlist, it makes sense to compare it with other ideas that may better fit your risk and return preferences.
- Spot potential bargains with solid fundamentals by scanning the 59 high quality undervalued stocks and see which companies look attractively priced relative to their quality.
- Focus on stability and capital preservation by reviewing the 68 resilient stocks with low risk scores to find businesses that score well on resilience and risk controls.
- Hunt for lesser known opportunities with strong metrics using the screener containing 25 high quality undiscovered gems and see which names others might be overlooking.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com